Kajiyama G, Takata K, Horiuchi I, Nakagawa M, Yamamoto M, Miyoshi A
Gastroenterol Jpn. 1983 Apr;18(2):98-108.
Lipids of HDL (high density lipoproteins) and their subfractions (HDL2 and HDL3), and LCAT activity (lecithin: cholesterol acyltransferase) were determined in hepatobiliary diseases without severe hyperbilirubinemia (less than 10 mg/dl). The decrease in major lipid constituents (cholesterol and phospholipids) of HDL was mainly attributable to the decrease in those of HDL3, except in some liver diseases of acute or severe stage (acute hepatitis in an acute stage and hepatoma) which were accompanied with a simultaneous moderate decrease in those of HDL2 and in fatty liver which showed a preferential decrease in those of HDL2. The LCAT activity also decreased in several diseases. Some of the hepatobiliary diseases, on the contrary, showed an increase in HDL-triglycerides (mostly in HDL3 and in some diseases also in HDL2) which might participate to some extent in secondary hyperlipidemia in the liver parenchymal diseases, although they were the minor lipid constituents of HDL. From results that HDL3- but not HDL2-cholesterol levels significantly correlated with serum total protein, albumin and choline esterase, it was suggested that the decrease in large constituents of HDL, particularly of HDL3, is caused by hepatocellular dysfunction which causes inhibition of protein and lipid syntheses in the liver in most of the hepatobiliary diseases except for fatty liver which has a preferential decrease in HDL2 lipids.
在无严重高胆红素血症（低于10mg/dl）的肝胆疾病中，测定了高密度脂蛋白（HDL）及其亚组分（HDL2和HDL3）的脂质以及卵磷脂胆固醇酰基转移酶（LCAT）活性。HDL主要脂质成分（胆固醇和磷脂）的减少主要归因于HDL3成分的减少，但某些急性或重症阶段的肝脏疾病（急性期急性肝炎和肝癌）除外，这些疾病同时伴有HDL2成分的中度减少，而脂肪肝则表现为HDL2成分的优先减少。几种疾病中LCAT活性也降低。相反，一些肝胆疾病显示HDL甘油三酯增加（主要在HDL3中，某些疾病中HDL2也有增加），尽管它们是HDL的次要脂质成分，但可能在一定程度上参与了肝实质疾病中的继发性高脂血症。从HDL3胆固醇水平而非HDL2胆固醇水平与血清总蛋白、白蛋白和胆碱酯酶显著相关的结果来看，提示在大多数肝胆疾病中，HDL主要成分尤其是HDL3成分的减少是由肝细胞功能障碍引起的，肝细胞功能障碍导致肝脏中蛋白质和脂质合成受到抑制，但脂肪肝除外，脂肪肝中HDL2脂质优先减少。
